Corden Pharma - A Full-Service CDMO

> CordenPharma is pleased to announce we joined the PSCI (Pharmaceutical Supply Chain Initiative) as Supplier Partner: https://lnkd.in/e_PyHZpH As of March 2025, after successfully fulfilling the requirements for supplier partnership, we have been selected to become a Supplier Partner in the second cohort of the PSCI - Pharmaceutical Supply Chain Initiative. PSCI brings together partners in the pharmaceutical and healthcare industry who share a common vision of ensuring acceptable working conditions, safe processes and facilities, economic development, and environmental sustainability in local communities. The PSCI audit program of our manufacturing sites assesses our performance against these responsible business practices and supply chain management standards. During the preparation phase for this partnership, CordenPharma excelled in several key areas, including the handling of high-potency compounds, behavior-based safety (BBS) programs, and risk management practices. This partnership not only addresses audit requirements from our customers but also supports the continued implementation of CordenPharma’s sustainable procurement program. William Cashin, Chief Quality & Compliance Officer at CordenPharma comments, “I am proud of the hard work across our global teams on sustainability. Our employees are delighted to achieve supplier partnership status and to demonstrate our commitment to the PSCI Principles. We look forward to sharing future audit results and Maturity Models with transparency and collaborating with customer PSCI members towards our common goal.” #CordenPharma #PSCI #cdmo #supplychain #pharmaceuticals #SHE #sustainability #highpotent #riskmanagement #behaviorbasedsafety #healthcare

Optimizing TFF for LNP Purification: Why It Matters After LNP formulations are produced, a buffer exchange step is essential to adjust pH and reduce ethanol content, ensuring stability and efficacy. Ultrafiltration/diafiltration (UF/DF) is then used to remove residual solvents and concentrate the RNA-LNP drug product into its final formulation buffer. But here’s the challenge: LNPs are shear-sensitive, and filtration processes must be carefully optimized to maintain high flux and throughput without compromising nanoparticle size and morphology. Understanding and optimizing critical process parameters, from membrane material and molecular weight cut-off (MWCO) to transmembrane pressure (TMP) and shear rate, is crucial for maintaining nanoparticle integrity. With deep expertise in purification and diafiltration, we know what it takes to optimize a TFF process for successful scale up - and we apply this expertise to LNP formulations too. Want to learn more? Join our Global Head of Development, Injectables and Nanomedicine, Dr. Umberto Romeo, at the 4th LNP Formulation & Process Development US Summit in Boston. If you’re not attending but would like to discuss LNP purification strategies, get in touch with us https://lnkd.in/e79WsNiq ! #cordenpharma #LNPs #lipidnanoparticles #CDMO #pharmaceuticals #pharma #RNAdelivery

Join us at CPHI Japan 2025, from April 9 - 11 in Tokyo! Meet our experts at booth 5N-03 to explore how we can support your development and manufacturing needs for high-quality APIs, Drug Products, and Lipid Excipients. Don't miss out Frieder Mitzel's presentation on Wednesday, April 9th, to know more about our fully integrated supply chain capabilities across our six technology platforms. We look forward to meeting you in Tokyo! Contact us if you want to schedule a meeting during the show dates: https://lnkd.in/e79WsNiq #cordenpharma #cdmo #cphijapan #cphijapan2025 #pharma #pharmaceuticals #pharmaindustry #drugdevelopment #drugmanufacturing

Struggling with poor API solubility? When salt or co-crystal formation isn’t an option, an amorphous dispersion could help improve bioavailability. One effective way to achieve this is hot melt extrusion (HME) - a solvent-free process that uses  a combination of mechanical energy and melting polymers above their glass transition temperature to effect molecular level mixing with an API, creating a stable amorphous form. At our Drug Product Innovation Centre of Excellence in Plankstadt, Germany, we use the Three-Tec ZE9 hot melt extruder to develop amorphous HME prototypes. In addition, we can perform vacuum compression molding (VCM) with a MeltPrep tool for very small scale preparations of HME surrogates. Once the best formulation is identified, we scale up manufacturing in our cGMP clinical trial area using the Thermo Scientific™ Process 11 Twin-Screw Extruder - seamlessly transitioning extrudate intermediates into capsules or tablets. Did you know? The twin screws of an extruder can be specifically designed for conveying, mixing, kneading, compacting, pressing, and more - making HME a versatile tool for pharmaceutical formulation! Looking for early-phase formulation development and bioavailability enhancement solutions? Learn more here: https://lnkd.in/e-Q5nWQZ or get in touch with our experts: https://lnkd.in/e79WsNiq #cordenpharma #cdmo #bioavailability #bioavailabilityenhancement #drugproduct #apis #hotmeltextrusion #HME #pharma 

"My Work Matters" campaign celebrates the unique value each employee brings to our organization. By sharing these stories, we want to foster our culture of appreciation, showing how individual efforts come together to drive a bigger purpose, making a difference in patients’ lives. #myworkmatters #companyculture #employerbranding #pharma #healthcare #healthforall

Day 1 at DCAT Week 2025! We kicked off the week at the DCAT Member Forum, where our CEO & President, Michael Quirmbach, announced our latest expansions for peptide development and manufacturing in Europe and the USA, including the construction of a greenfield peptide facility outside Basel, Switzerland (read more about it in our press release https://lnkd.in/e_CtrPtr...). In addition, we were pleased to share the latest news about our end-to-end integrated supply partnership for a GLP-1 drug candidate to provide large-scale peptide drug substance manufacturing, fill-finish for subcutaneous formulation and oral solid dosage manufacturing for oral peptide formulation. (read more about it in our press release: https://lnkd.in/ec-cxb5U...).   Our team is ready and looking forward to meeting with existing customers, partners, and new industry professionals to explore potential collaborations and ways we can support your complex pharmaceutical modalities across the entire drug product lifecycle. Get in touch with us if you want to book a meeting with our experts during these upcoming days in New York: https://lnkd.in/gV4QuMDZ #cordenpharma #dcatweek #cdmo #pharma #pharmaceuticals #apimanufacturing #drugproduct #peptides #injectables #oralpeptides

Struggling with poor API dissolution? When an API is dissolution-rate challenged, reducing the particle size can significantly improve dissolution and bioavailability. One effective approach is nanomilling, which dramatically increases surface area - leading to faster API dissolution and possibly an increase in solubility. In our non-GMP R&D area at our Drug Product Innovation Centre of Excellence in Plankstadt, Germany, we use a Netzsch DeltaVita® 1 nanomill (wet ball mill) to develop small-scale nano-suspension prototypes. The process involves a liquid vehicle that usually contains a surface-active agent which helps form a stable colloidal suspension while controlling particle size. Nanomilling is also a closed-system process, meaning a controlled environment for consistent results and operator protection—especially important for highly potent APIs. Plus, it’s an efficient, robust, and scalable operation. Did you know? Nanomills can also be used for homogenization to produce liposomes and emulsions, as well as mixing difficult or highly viscous components! Looking for early-phase formulation development and bioavailability enhancement solutions? Learn more here: https://lnkd.in/e-Q5nWQZ or get in touch with our experts: https://lnkd.in/e79WsNiq #cordenpharma #cdmo #bioavailability #bioavailabilityenhancement #drugproduct #drugformulation #apis #pharma

>11 March: CordenPharma & Viking Therapeutics Sign Strategic Partnership to Support GLP-1 Drug Candidate: https://lnkd.in/ekwx2DUw CordenPharma is pleased to announce the signing of a strategic partnership with Viking Therapeutics, Inc. (Nasdaq: VKTX), a clinical-stage company focused on developing novel therapies for metabolic and endocrine disorders. Under this multi-year supply contract, CordenPharma provides development and manufacturing services for clinical and commercial demand of Viking Therapeutics’ GLP-1 drug candidate VK2735, a Dual GLP-1/GIP Receptor Agonist, across the full supply chain from drug substance to drug product for both its subcutaneous and oral peptide formulations. By leveraging our advanced manufacturing facilities, this uniquely integrated capability incorporates CordenPharma’s extensive experience in large-scale peptide drug substance, sterile injectable fill-finish, and oral solid dosage drug product manufacturing to ensure seamless development and commercialization of Viking Therapeutics’ VK2735 drug candidate. With built-in redundancy through multiple drug substance sites across our global facility network, CordenPharma is well-positioned to ensure a secure and uninterrupted supply chain throughout the lifecycle of Viking Therapeutics’ VK2735 drug candidate. Dr. Michael Quirmbach, President & CEO of the CordenPharma Group, comments: “We are proud to support Viking Therapeutics with a strong end-to-end offering for their complex modalities, from peptide drug substance to drug product, for this innovative VK2735 drug candidate. Our global teams are excited to provide true integration of our expertise across the pharma supply chain to meet the increasing demand for GLP-1 peptide therapeutics and ultimately, improve patient outcomes.” #CordenPharma #VikingTherapeutics #CDMO #VK2735 #GLP1 #GIP #diabetes #obesity #NASH #peptides #peptideagonists #oralpeptides #injectables #pharmamanufacturing #pharmaceuticals #subcutaneous #oralformulation #IntegratedSupply

Today, we celebrate the strength, resilience, and achievements of women across the world. From fighting for the right to vote to breaking barriers in science, sports, politics, and business, women have continuously shaped history and inspired future generations. Throughout history, women have transformed the fields of science and healthcare, making groundbreaking discoveries that have saved millions of lives. At CordenPharma, we are extremely proud of all the women across our organization. No matter their role, each one plays a key part in our success. We are committed to equality, diversity, and empowerment, fostering a culture that champions inclusion. Let’s continue working towards a future where every woman can pursue her dreams without limitations. #InternationalWomensDay #IWD2025 #WomenEmpowerment #GenderEquality #InspireInclusion

> 5 March: CordenPharma Expands Peptide Platform with >€500m Greenfield Facility Construction near Basel Switzerland: https://lnkd.in/ek2ygNiQ We are pleased to announce significant progress on our growth initiatives with a >€1 billion strategic investment in peptide development and manufacturing. Our ambitious expansion plans are set to propel our Peptide Platform business beyond the €1 billion sales milestone by 2028, reinforcing CordenPharma’s position as one of the largest peptide manufacturing partners leading the CDMO peptide space. 🚀 As part of this strategy, we have finalized plans to establish a state-of-the-art peptide manufacturing facility located at GETEC Switzerland Park in Muttenz, just 8 km outside Basel – a major biotech and pharma hub within Europe. The decision to locate the plant near Basel is supported by several key advantages, including efficient infrastructure, optimal transportation networks, proximity to the Basel talent pool, and a surrounding industrial park that ensures sustainable operational efficiency in a well-established manufacturing ecosystem with a clear strategic path to net-zero. The >€500 million Swiss investment will feature small- to large-scale SPPS reactors for GLP-1 and non-GLP-1 peptide projects with a total SPPS reactor capacity of more than 5,000 L, advanced automation, cutting-edge digitalization, and innovative peptide production technologies that ensure compliance with the most stringent regulations, including BLA requirements. We are proud to generate over 300 new jobs, contributing to economic growth and innovation of the region. Our CordenPharma Colorado US expansion will more than double the existing reactor capacity with an additional 25,000 L of SPPS capacity – making it a total reactor capacity of >42,000 L by 2028. Dr. Michael Quirmbach, President & CEO of CordenPharma Group comments: “We are excited to announce the construction of a state-of-the-art manufacturing plant just outside Basel, Switzerland. The new facility is designed to deliver flexible and efficient peptide manufacturing to meet the growing demand of innovative peptide medicines for our customers and ultimately, patients.” Judith Charpentier, Co-Head Flagship Fund and Head of Healthcare at Astorg comments: “CordenPharma’s bold expansion reflects its leadership in addressing the growing demand for peptide manufacturing. As a long-term investor, we are fully committed to supporting this growth, combining industrial excellence with strategic investment to strengthen CordenPharma’s position as a leading global CDMO.” #CordenPharma #cdmo #peptides #spps #peptidetherapeutics #GLP1s #diabetes #obesity #peptideagonists #oralpeptides #injectables #pharmaceuticals #switzerland #basel #pharmajobs #healthcare #supplychain